Proficio Capital Partners LLC Purchases New Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Proficio Capital Partners LLC acquired a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,558 shares of the biotechnology company’s stock, valued at approximately $210,000.

Several other large investors have also recently bought and sold shares of the company. Berkshire Money Management Inc. bought a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $107,000. Fiduciary Alliance LLC bought a new position in Anavex Life Sciences in the fourth quarter valued at approximately $119,000. D.A. Davidson & CO. acquired a new stake in Anavex Life Sciences during the 4th quarter worth $122,000. Orion Capital Management LLC raised its position in shares of Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 10,000 shares during the last quarter. Finally, PVG Asset Management Corp acquired a new position in shares of Anavex Life Sciences in the 3rd quarter valued at $74,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Stock Down 0.9 %

Shares of NASDAQ AVXL opened at $8.90 on Thursday. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $14.44. The stock has a market cap of $757.07 million, a price-to-earnings ratio of -16.18 and a beta of 0.94. The company’s fifty day moving average is $9.48 and its 200-day moving average is $7.99.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. On average, research analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AVXL has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research note on Tuesday, February 18th. D. Boral Capital restated a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a research report on Wednesday, February 12th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.